Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22472919 | 0.92 | OPRK1 (0.30) | — | |
| SCHEMBL17101492 | 0.89 | CHRM1 (0.40) | CHRM1 | |
| SCHEMBL21597923 | 0.88 | CHRM1 (0.33) | CHRM1LMNAPOLB | |
| SCHEMBL19965839 | 0.83 | TP53 (0.47) | CHRM1ALDH1A1MAPK1TP53L3MBTL1 | |
| SCHEMBL17101344 | 0.81 | CHRM1 (0.41) | CHRM1 | |
| SCHEMBL18075934 | 0.80 | CHRM4 (0.39) | CHRM1ALDH1A1MAPK1TP53L3MBTL1 | |
| SCHEMBL20942028 | 0.80 | CHRM1 (0.38) | CHRM1L3MBTL1 | |
| SCHEMBL22449322 | 0.79 | — | — | |
| SCHEMBL23289874 | 0.79 | CHRM1 (0.30) | CHRM1CCR5 | |
| SCHEMBL22472866 | 0.79 | LMNA (0.36) | CHRM1LMNAMAPK1TP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885ALDH1A1 2016/4885LMNA 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.